Professional Summary
Specializing In
Practice Locations
Patient Ratings
Referring Physicians
Biography
Dr. Wen-Kai Weng specializes in the treatment of non-Hodgkin's lymphoma (NHL), his basic research interest is immunotherapy for lymphoma and cancer, with two components: tumor specific targeting therapy and allogeneic transplant. He is currently working on new strategies to target patient-specific tumor using antibody along with effector cells. He is also conducting clinical study looking at the clinical efficacy of allogeneic transplant in patients with cutaneous lymphoma.
View Full Biography
Professional Summary
Education & Certifications
- Board Certification: American Board of Internal Medicine, Medical Oncology (2021)
- Fellowship, Stanford University, Medical Oncology (2002)
- Residency, University of Texas-Houston, Internal Medicine (1999)
- Internship, University of Texas-Houston, Internal Medicine (1997)
- PhD, University of Minnesota, Pathobiology/Immunology (1996)
- MD, ChungShan Medical and Dental College, Medicine (1988)
Honors & Awards
- Charles and Dorothy Andrew Bird Award, Sigma Xi Scientific Research Society (1996)
- Department of Medicine Master Teacher Award, Stanford University (2022)
- Developmental Research Award, Stanford Cancer Institute (2012-2013)
- Developmental Research Award, Stanford University Cancer Center (2009-2010)
- Division Teaching Award, BMT, Stanford University (2009, 2010, 2012, 2015, 2016, 2018, 2019)
- Doctoral Dissertation Award, University of Minnesota Graduate School (1995)
- Fellowship, Lymphoma Research Foundation (2002-2004)
- ITI Seed Grant Award, Institute for Immunity, Transplantation and Infection, Stanford University (2011-2012)
- K08 Clinical Scientist Career Development Award, NIH/NCI (2005-2009)
- Predoctoral National Research Service Award, NIH/NIAID (1994-1995)
- Translational Research Grant, Stanford Cancer Institute (2014-2015)
Memberships
- Co-Director, Stanford Cancer Immunotherapy and Blood & Marrow Transplantation Symposium (2018 - Present)
Administrative Appointments
- Co-Director, Stanford Multidisciplinary Cutaneous Lymphoma Clinic (2014 - Present)
- Director, Blood and Marrow Transplantation/Cellular Therapy (BMT/CT) Fellowship Program (2015 - Present)
- Scientific Advisory Board, Lymphoma Research Foundation (2011 - 2012)
Publications
-
Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma
Weng, W. K., & Levy, R. (2001). Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. BLOOD, 98(5), 1352–57. -
Hepatitis C virus (HCV) and lymphomagenesis
Weng, W. K., & Levy, S. (2003). Hepatitis C virus (HCV) and lymphomagenesis. LEUKEMIA & LYMPHOMA, 44(7), 1113–20. -
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
Weng, W. K., & Levy, R. (2003). Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 21(21), 3940–47. -
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells
Luqman, M., Klabunde, S., Lin, K., Georgakis, G. V., Cherukuri, A., Holash, J., … Younes, A. (2008). The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. BLOOD, 112(3), 711–20. -
A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma
Racila, E., Link, B. K., Weng, W.-K., Witzig, T. E., Ansell, S., Maurer, M. J., … Weiner, G. J. (2008). A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma. CLINICAL CANCER RESEARCH, 14(20), 6697–6703. -
Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma
Timmerman, J. M., Vose, J. M., Czerwinski, D. K., Weng, W.-K., Ingolia, D., Mayo, M., … Levy, R. (2009). Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. LEUKEMIA & LYMPHOMA, 50(1), 37–46. -
TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., Miklos, D. B., … Lowsky, R. (2009). TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 114(5), 1099–1109. -
Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma
Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., … Horning, S. J. (2010). Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16(8), 1145–54. -
Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma
Chen, A. I., Negrin, R. S., McMillan, A., Shizuru, J. A., JOHNSTON, L. J., Lowsky, R., … Stockerl-Goldstein, K. (2012). Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. BONE MARROW TRANSPLANTATION, 47(4), 516–21. -
Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., Lowsky, R., … Negrin, R. S. (2011). Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1679–87. -
The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients
Kelly-Sell, M. J., Kim, Y. H., Straus, S., Benoit, B., Harrison, C., Sutherland, K., … Rook, A. H. (2012). The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. AMERICAN JOURNAL OF HEMATOLOGY, 87(4), 354–60. -
Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence
Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., Lowsky, R., … Miklos, D. B. (2012). Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. BLOOD, 119(25), 6145–54. -
Cancer Vaccines and T Cell Therapy
Rezvani, K., Brody, J. D., Kohrt, H. E., Logan, A. C., Advani, R., Czerwinski, D. K., … Barrett, J. (2013). Cancer Vaccines and T Cell Therapy. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(1), S97–S101. -
SIGNALING THROUGH CD19 ACTIVATES VAV MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY AND INDUCES FORMATION OF A CD19/VAV/PHOSPHATIDYLINOSITOL 3-KINASE COMPLEX IN HUMAN B-CELL PRECURSORS
Weng, W. K., Jarvis, L., & LeBien, T. W. (1994). SIGNALING THROUGH CD19 ACTIVATES VAV MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY AND INDUCES FORMATION OF A CD19/VAV/PHOSPHATIDYLINOSITOL 3-KINASE COMPLEX IN HUMAN B-CELL PRECURSORS. JOURNAL OF BIOLOGICAL CHEMISTRY, 269(51), 32514–32521. -
FUNCTIONAL EFFECT OF IL-7-ENHANCED CD19 EXPRESSION ON HUMAN B-CELL PRECURSORS
Wolf, M. L., Weng, W. K., STIEGLBAUER, K. T., Shah, N., & LeBien, T. W. (1993). FUNCTIONAL EFFECT OF IL-7-ENHANCED CD19 EXPRESSION ON HUMAN B-CELL PRECURSORS. JOURNAL OF IMMUNOLOGY, 151(1), 138–148. -
Differential induction of DNA-binding activities following CD19 cross-linking in human B lineage cells
Weng, W. K., Shah, N., O'Brien, D., Van Ness, B., & LeBien, T. W. (1997). Differential induction of DNA-binding activities following CD19 cross-linking in human B lineage cells. JOURNAL OF IMMUNOLOGY, 159(11), 5502–5508. -
Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
Weng, W. K., Czerwinski, D., Timmerman, J., Hsu, F. J., & Levy, R. (2004). Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. JOUNRAL OF CLINICAL ONCOLOGY, 22. -
Immune-mediated antitumor effects with antibody therapy.
Immune-mediated antitumor effects with antibody therapy. (2005). American Society of Clinical Oncology Educational Book. -
Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless their response to induction chemotherapy.
Weng, W. K., Czerwinski, D., & Levy, R. (2007). Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless their response to induction chemotherapy. BLOOD, 109. -
Immunoglobulin G Fc Receptor Polymorphisms Do Not Correlate with Response to Chemotherapy or Clinical Course in Patients with Follicular Lymphoma
Weng, W. K., & Levy, R. (2009). Immunoglobulin G Fc Receptor Polymorphisms Do Not Correlate with Response to Chemotherapy or Clinical Course in Patients with Follicular Lymphoma. LEUKEMIA & LYMPHOMA, 50(9). -
Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma
Weng, W. K., Armstrong, R., Arai, S., Desmarais, C., Hoppe, R., & Kim, Y. H. (2013). Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma. SCIENCE TRANSLATIONAL MEDICINE, 5(214). -
Genetic polymorphism of the inhibitory IgG Fc receptor FcRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab
Weng, W. K., & Levy, R. (2009). Genetic polymorphism of the inhibitory IgG Fc receptor FcRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. LEUKEMIA & LYMPHOMA, 50(5:723-727). -
The IgG Fc Receptor Fc?RIIIa 158 V/F Polymorphism is Correlated with Rituximab-Induced Neutropenia after Autologous Transplantation in Patients with Non-Hodgkin Lymphoma
Weng, W. K., Negrin, R., Lavori, P., & Horning, S. J. (2010). The IgG Fc Receptor Fc?RIIIa 158 V/F Polymorphism is Correlated with Rituximab-Induced Neutropenia after Autologous Transplantation in Patients with Non-Hodgkin Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 28. -
Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated IncRNAs and novel transcripts
Lee, C. S., Ungewickell, A., Bhaduri, A., Qu, K., Webster, D. E., Armstrong, R., … Khavari, P. A. (2012). Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated IncRNAs and novel transcripts. BLOOD, 120. -
Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.
Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., Arai, S., … Lowsky, R. (2014). Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms. Biology of Blood and Marrow Transplantation , 20(6), 837–43. -
European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation
Medeiros, B. C., Tian, L., Robenson, S., Laport, G. G., JOHNSTON, L. J., Shizuru, J. A., … Lowsky, R. (2014). European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. BLOOD CANCER JOURNAL, 4. -
Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2.
Ungewickell, A., Bhaduri, A., Rios, E., Reuter, J., Lee, C. S., Mah, A., … Khavari, P. A. (2015). Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2. Nature Genetics, 47(9), 1056–60. -
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., … Horwitz, S. M. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of Clinical Oncology , 33(32), 3750–58. -
Gain of CD26 expression on the malignant T-cells in relapsed erythrodermic leukemic mycosis fungoides.
Cedeno-Laurent, F., Wysocka, M., Obstfeld, A. E., Novoa, R. A., Vittorio, C. C., Kim, E. J., … Rook, A. H. (2017). Gain of CD26 expression on the malignant T-cells in relapsed erythrodermic leukemic mycosis fungoides. Journal of Cutaneous Pathology. -
HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.
Spinner, M. A., Fernández-Viña, M., Creary, L. E., Quinn, O., Elder, L., Arai, S., … Rezvani, A. R. (2017). HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Advances, 1(17), 1347–57. -
Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation
Muffly, L., Sheehan, K., Armstrong, R., Jensen, K., Tate, K., Rezvani, A. R., … Lowsky, R. (2018). Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation. BLOOD ADVANCES, 2(6), 681–90. -
Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome.
Dai, J., Almazan, T. H., Hong, E. K., Khodadoust, M. S., Arai, S., Weng, W.-K. K., & Kim, Y. H. (2018). Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome. JAMA Dermatology. -
Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation
Veeraputhiran, M., Yang, L., Sundaram, V., Arai, S., Lowsky, R., Miklos, D., … Johnston, L. (2017). Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 23(10), 1744–48. -
Effect of voriconazole on risk of nonmelanoma skin cancer after hematopoietic cell transplantation
Kuklinski, L. F., Li, S., Karagas, M. R., Weng, W.-K., & Kwong, B. Y. (2017). Effect of voriconazole on risk of nonmelanoma skin cancer after hematopoietic cell transplantation. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 77(4), 706–12. -
Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients
Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., … Negrin, R. S. (2019). Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI INSIGHT, 4(10). -
Volumetric Modulated Arc Therapy and 3-Dimensional Printed Bolus in the Treatment of Refractory Primary Cutaneous Gamma Delta Lymphoma of the Bilateral Legs
Obeid, J.-P., Gutkin, P. M., Lewis, J., Skinner, L., Wang, E. B., Khodadoust, M. S., … Hiniker, S. M. (2019). Volumetric Modulated Arc Therapy and 3-Dimensional Printed Bolus in the Treatment of Refractory Primary Cutaneous Gamma Delta Lymphoma of the Bilateral Legs. PRACTICAL RADIATION ONCOLOGY, 9(4), 220–25. -
Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Arai, S., Johnston, L. J., … Lowsky, R. (2019). Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. Blood Advances, 3(16), 2454–64. -
Pityriasis rubra pilaris-like graft-vs-host disease following allogeneic stem cell transplant in two patients.
Wang, J. Y., Tabata, M. M., Pugliese, S., Phillips, D., Kim, J., Weng, W.-K. K., & Kwong, B. Y. (2019). Pityriasis rubra pilaris-like graft-vs-host disease following allogeneic stem cell transplant in two patients. Clinical Case Reports, 7(12), 2491–2494. -
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., … Levy, R. (2020). Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. The Journal of Experimental Medicine, 217(9). -
Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.
Lemieux, C., Muffly, L. S., Rezvani, A., Lowsky, R., Iberri, D. J., Craig, J. K., … Sidana, S. (2020). Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. Bone Marrow Transplantation. -
Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.
Weng, W.-K. K., Arai, S., Rezvani, A., Johnston, L., Lowsky, R., Miklos, D., … Kim, Y. H. (2020). Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Advances, 4(18), 4474–82. -
Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.
Lemieux, C., Johnston, L. J., Lowsky, R., Muffly, L. S., Craig, J. K., Shiraz, P., … Sidana, S. (2020). Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. -
CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.
Baird, J. H., Frank, M. J., Craig, J., Patel, S., Spiegel, J. Y., Sahaf, B., … Muffly, L. (2020). CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma. Blood. -
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., … Sidana, S. (2021). Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. BLOOD ADVANCES, 5(1), 143–55. -
Pembrolizumab in mycosis fungoides with PD-L1 structural variants.
Beygi, S., Fernandez-Pol, S., Duran, G., Wang, E. B., Stehr, H., Zehnder, J. L., … Khodadoust, M. S. (2021). Pembrolizumab in mycosis fungoides with PD-L1 structural variants. Blood Advances, 5(3), 771–74. -
Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Liang, E. C., Muffly, L. S., Shiraz, P., Shizuru, J. A., Johnston, L., Arai, S., … Sidana, S. (2021). Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy. -
Radiation Therapy for Primary Cutaneous Gamma Delta Lymphoma Prior to Stem Cell Transplantation.
Wu, Y. F., Skinner, L., Lewis, J., Khodadoust, M. S., Kim, Y. H., Kwong, B. Y., … Hiniker, S. M. (2021). Radiation Therapy for Primary Cutaneous Gamma Delta Lymphoma Prior to Stem Cell Transplantation. Cancer Investigation, 1–11. -
Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.
Johnsrud, A., Ladha, A., Muffly, L., Shiraz, P., Goldstein, G., Osgood, V., … Sidana, S. (2021). Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era. Transplantation and Cellular Therapy. -
Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.
Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., … Sidana, S. (2021). Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. Bone Marrow Transplantation. -
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., … Miklos, D. B. (2021). CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine. -
Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.
Muffly, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., … Miklos, D. B. (2021). Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. Blood Advances, 5(16), 3147–3151. -
NUTRITIONAL DEFICIENCY CONTRIBUTING TO REFRACTORY ERYTHRODERMA IN HEMATOPOETIC CELL TRANSPLANT PATIENTS: DISTINCTIVE CLINICAL AND HISTOPATHOLOGICAL FINDINGS.
Winge, M. C., Rieger, K. E., Kim, J., Weng, W.-K., Johnston, L. J., Miklos, D. B., … Kwong, B. Y. (2021). NUTRITIONAL DEFICIENCY CONTRIBUTING TO REFRACTORY ERYTHRODERMA IN HEMATOPOETIC CELL TRANSPLANT PATIENTS: DISTINCTIVE CLINICAL AND HISTOPATHOLOGICAL FINDINGS. Journal of the American Academy of Dermatology. -
Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy.
Johnsrud, A. J., Craig, J., Baird, J. H., Spiegel, J. Y., Muffly, L., Zehnder, J. L., … Sidana, S. (2021). Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy. Blood Advances. -
Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy
Johnsrud, A., Craig, J., Baird, J., Spiegel, J., Muffly, L., Zehnder, J., … Sidana, S. (2021). Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. BLOOD ADVANCES, 5(21), 4465–4475. -
Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report.
Bankova, A. K., Caveney, J., Yao, B., Ramos, T. L., Bogeholz, J., Heydari, K., … Arai, S. (1800). Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report. Transplantation and Cellular Therapy. -
Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era.
Liang, E. C., Craig, J., Torelli, S., Cunanan, K., Iglesias, M., Arai, S., … Muffly, L. (2022). Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era. Transplantation and Cellular Therapy. -
Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.
Spinner, M. A., Sica, R. A., Tamaresis, J. S., Lu, Y., Chang, C., Lowsky, R., … Arai, S. (2023). Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. Blood. -
Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD.
Bader, C. S., Pavlova, A., Lowsky, R., Muffly, L., Shiraz, P., Arai, S., … Meyer, E. (2023). Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD. Blood Advances. -
Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma.
Nie, E. H., Su, Y.-J. J., Baird, J. H., Agarwal, N., Bharadwaj, S., Weng, W.-K. K., … Frank, M. J. (2024). Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma. Blood Advances. -
Clinical characteristics, treatment patterns, and outcomes of cytotoxic cutaneous T-cell lymphomas.
Mou, E., Fernandez-Pol, S., Li, S., Rieger, K. E., Novoa, R., Suarez, C. J., … Khodadoust, M. S. (2024). Clinical characteristics, treatment patterns, and outcomes of cytotoxic cutaneous T-cell lymphomas. American Journal of Hematology. -
A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell Lymphoma.
Moustafa, M. A., Ramdial, J. L., Tsalatsanis, A., Khimani, F., Dholaria, B., Bojanini, L., … Murthy, H. S. (2024). A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell Lymphoma. Transplantation and Cellular Therapy. -
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.
Hamilton, M. P., Craig, E., Gentille Sanchez, C., Mina, A., Tamaresis, J., Kirmani, N., … Miklos, D. B. (2024). CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. Blood Advances. -
Tabelecleucel for EBV+ PTLD following allogeneic HCT or SOT in a multicenter expanded access protocol.
Nikiforow, S., Whangbo, J. S., Reshef, R., Tsai, D. E., Bunin, N. J., Abu-Arja, R. F., … Prockop, S. E. (2024). Tabelecleucel for EBV+ PTLD following allogeneic HCT or SOT in a multicenter expanded access protocol. Blood Advances. -
Management of post-autologous transplant relapse in patients with T-cell lymphomas.
Veilleux, O., Socola, F., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., … Weng, W.-K. K. (2024). Management of post-autologous transplant relapse in patients with T-cell lymphomas. American Journal of Hematology. -
Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.
Bharadwaj, S., Lau, E., Hamilton, M. P., Goyal, A., Srinagesh, H., Jensen, A., … Dahiya, S. (2024). Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma. Journal for Immunotherapy of Cancer, 12(7). -
A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.
Srinagesh, H. K., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M. P., Egeler, E., … Muffly, L. (2024). A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia. Blood. -
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.
Frank, M. J., Baird, J. H., Kramer, A. M., Srinagesh, H. K., Patel, S., Brown, A. K., … Miklos, D. B. (2024). CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study. Lancet (London, England).
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma
- Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma
- Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies
- Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
- TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD
- Transplantation for Patients With Chronic Lymphocytic Leukemia
- Targeted Therapy of Bronchiolitis Obliterans Syndrome
- Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
Practice Locations
Blood and Marrow Transplant Program (BMT) - 875 Blake Wilbur Drive Palo Alto, CA
Palo Alto, CA
Blood and Marrow Transplant Program (BMT) - 875 Blake Wilbur Drive
875 Blake Wilbur Drive, Clinic E, 1st Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(129 reviews)
Dr. Weng presents a very personable and informative approach in sharing information with me that I really appreciate.
A very good doctor thank you so much
Dr. Weng listened carefully to my report on recent health issues and included me in his care plan, explaining his thoughts in an easy to understand way. He’s an outstanding physician.
Dr. Weng is an excellent BMT doctor. He is one of your best doctors!
We love Dr. Weng so much, him & his team are amazing.
He’s the best!
Dr. Weng is a wonderful doctor. I have the highest opinion of him!
Very good and understanding doctor.
Great doctor 1000% satisfied with my treatment.
Awesome doctor! Listens well to all your concerns!
He is a good doctor
He’s the best. Very caring. Very thorough. Always involves me in care decisions, and explains his thinking clearly, in ways that I can understand.
Dr. Weng proved outstanding care, as always.
None everything was satisfied and he had answered all my questions
Dr. Weng is a wonderful Dr. I find him open and knowledgeable. Very personable.
He answered all my concerns and he's a good doctor
Excellent doctor. Understanding and compassionate.
When I was referred to Dr. Weng as a stem-cell transplant candidate, I was very sick. My two prior chemotherapy regimens during the year prior were not successful. Dr. Weng is the oncologist who saved my life. I will always be grateful to him and hope that he can be my oncologist forever.
Very good doctor
Dr. Weng is excellent of what he does.
I think he is easy to talk to and straight forward. I have confidence in him.
Dr. Weng provided excellent care, explained the care plan thoroughly, and included me in his decision-making process.
Dr. Weng has always treated me with kindness, respect and concern.
I think he is easy to talk to and is very approachable.
Poor communication
Dr. Weng was very informative and informative ðŸ‘
He seems to be busy. I probably had less than 10 minutes talking with. He seems to be in a hurry to leave, so I talked more to the assistant than him.
Dr Weng is an excellent doctor.
I would follow with Dr Weng and can't wait to see next proceture. Thank you Dr Weng
Dr. Weng did a great job. He was thorough, included me in my care decisions, and explained everything thoroughly.
Dr Weng is very professional, friendly, and knowledgeable. Furthermore, he even remembers personal details not related to the medical. I feel being heard and valued.
Very nice
I felt very comfortable when meeting with doctor Wayne, he made sure I understood things with questions I asked.
Dr. Weng is an excellent physician and I am very grateful that he is my doctor.
Very caring and thorough. Very happy to have him as my doctor.
Very thorough, encourages questions
Dr Wen Kai Weng seems to be a very kind, knowledgeable compassionate doctor I feel blessed to have had the pleasure of meeting him.
As always, Dr. Weng provided excellent care and included me in the care plan decisions.
Dr. Weng is very proactive in my care. He is very interested in my well-being and overall outcome in this disease process. I appreciate his skill and ability to treat me through this process. He’s a very good physician and very knowledgeable. I feel I’m getting the best care available.
Drs. Kim and Khodadoust are the best
We were impressed with the help we received.
Excellent
I am very happy with Dr. Weng.
An excellent physician.
Doctor Weng is very professional and speaks to me with warmth and kindness. He is through with what needs to be done next and follows up with my oncologist.
Wen-Kai is very caring and thorough with his patients
Dr. Weng was on time, listened to my concerns, and explained his care plan thoroughly. As always, an excellent visit.
I will be eternally grateful to Dr. Weng for the excellent care I received from him, his team, and the staff at Stanford during my illness.
I think the world of Dr. Weng and hope he can be my physician for the rest of my life!
Dr. Weng did an excellent job, as always.
good doctor
Excellent doctor! Easy to talk to and is a very good listener.
Terrific sense of humor.
Excellent care as always
Dr. Weng is the best
Good doctor
I'm very pleased with Dr. Weng. I feel I'm getting excellent care.
He is caring, thorough and professional
Always pleasure communicating with Dr. Weng..
HE HAS ALWAYS BEEN PROFESSIONAL, PROVIDED AN OPPORTUNITY FOR MY QUESTIONS AND ANSWERED THEM IN AN EFFICIENT MANNER.
I AM TOTALLY PLEASED WITH DR. WENG AND ALWAYS LOOK FORWARD TO OUR VISITS.
I FIND HIM PLEASANT, SMILEY AND PROFESSIONAL IN ALL WAYS.
He has a lot of knowledge about cancer and how to treat it and I felt very comfortable with everything he told me.
Great Doctor
Excellent physician.
Great doctor
Wen-Kai is a breath of fresh air.
The doctors both were kind, listened and explained the process. The social worker took time to listen and take notes - asked me questions, & listened to my concerns.
Positive, constructive experience.
Good communicator!
Doctor Weng is a good doctor, he's caring and explained well so we can understand.
Dr. Weng is the best physician I have ever had! Thank you!
Dr. Weng did an excellent job explaining his recommendation.
Good.
We love Dr. Weng!
Dr. Weng rocks.
I could not have asked for a better or more competent provider to get me through a transplant.
Dr. Weng was very caring and unlike most doctors I have seen lately took the time necessary to explain everything.
Love my dr.
Dr. Weng was great.
I am - very pleased with the care that I am receiving from my doctor.
Dr. Weng is fantastic!
Dr. Weng, Wen-Kai is a love, always of good attitude and very affectionate.
Doctor Weng is a caring doctor and answer all my questions, also nurse Amanda too, we really appreciated the teams of Doctor Weng.
For me its the best doctor since my illness started.
Thank you! Dr. Weng for saving my life! You & your staff are amazing people.
Dr. Weng and his staff are awesome.
I would recommend you to other people for the reason the doctors are very good & secure.
Dr. Weng is undoubtedly one of the most caring and informative doctors I have ever seen!!
I feel fortunate to have Dr. Weng as my primary BMT doctor.
Dr. Weng is very friendly and personal.
Dr. Weng is very caring and very nice.
The care provider made the information easy to understand.
Dr. Weng give excellent care and very knowledgeable and professional. 10. For sure!
I also appreciate his sense of humor. And it's always appropriate.
Speaking to the doctor and how he explained everything.
Dr. Weng is the best! He is knowledgeable about all my medications & treatment. He is kind & funny & oh so personable - I am so thankful for him!
Dr. Wen is exceptionally skilled at explaining complex, serious issues & adjusting his delivery to my level of understanding. Instills confidence.
Because to me they explained everything well that I needed.
Dr. Weng is very knowledgeable & professional, caring, loving & compassionate to patients & their families. God bless him! He is the best!
Dr. Weng is the worst in describing in lay terms the mechanism of multiple myeloma.
Couldn't have been better! Best personable staff I have EVER experienced!
Excellent!
Dr. Weng is always thorough, professional and informed. He has been my doctor for 4 years and I've never had a complaint.
The care provider listen and answer all my concern.
Staff is and always the best. I'm always pleased with every visit and each and every staff member is always great.
Dr. Weng is very sensitive & thoughtful I have complete confidence in the care he provides.
Dr. Weng is awesome!
Excellent care.
Did not really discuss alternative care options.
Dr. Weng is awesome - I am so thankful that I was connected with him.
Dr. Weng in wonderful he's always willing to discuss my concerns & wonderfully upbeat. Our visits are always a pleasant experience even when it's not what I want to hear.
Dr. Weng has my total trust. We love him -
Dr. Weng is kind and thorough. He never rushes me or hurries me along. He is SMART and I have a lot of confidence in him.
Felt in very capable hands.
Will make every effort to see me before my appointment time whenever he is available.
I have a great amount of trust in my oncology team; Dr. Weng and Suzanne are easy to communicate with and show a lot of concern and support in my treatments and recovery.
Dr. Weng is the "man" he explained everything to me to where I could understand what is going on with my health. The social worker was great (ANA STAFFORD). And so was the RN (INNA KAPLAN) I was so comfortable talking with them.
Great experience!
Dr. Weng is excellent.
He saw what was happening, said, "I have no idea what this is, this is how I think we should treat it", then discussed the various possible treatments. I was impressed!
Dr. Weng who very familiar with my medical history and spent a lot of the answering my questions.
Dr. Weng is excellent.
My husband & I were VERY impressed with the knowledge of the whole staff!
Dr. Weng was terrific! Smart, responsive, optimistic, sensitive & knowledgeable.
Dr. Wang is always very efficient and kind. He is also very good at explaining medical terminology and procedures and procedures in a way that I could understand.
Very impressed - best explanation of my condition/tx options.
This appointment was a follow up to my treatment.
I love Stanford and I recommend to other who needs help.
Dr. Weng is the best!
Dr. Weng inspires complete confidence with his knowledge, experience & positive, friendly attitude.
She doesn't explain until asked; then does in helpful way.
Good.
I am glad Dr. Wang is my doctor. I have also had good experience with Dr. Miklos in the hospital.
View More
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records